Loading stock data…
Esperion Therapeutics (ESPR)
$3.18
Market Closed
Esperion Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States.
Historical Price
Price (Candle)
Synthesizing Whystock Narrative...
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $80.10M↓ | $168.45M↑ | $87.31M↑ | $82.39M↑ | $65.00M |
| Gross Profit | $45.53M↓ | $140.59M↑ | $46.02M↓ | $53.84M↑ | $33.46M |
| Operating Income | -$6.58M↓ | $85.23M↑ | -$9.96M↓ | $7.09M↑ | -$22.10M |
| Net Income | -$25.20M↓ | $61.83M↑ | -$31.33M↓ | -$12.72M↑ | -$40.45M |
Peer Comparison
JNJUNHPFE
Fundamentals
Esperion Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXL...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$815.60M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
2.41%
Volume
Today's trading volume
59.09M
Recent News
Esperion Therapeutics Clears Key Hurdle as Stockholders Approve Essence Merger
Stockholders of Esperion Therapeutics (NASDAQ:ESPR) approved the company’s merger agreement with Essence Parent and Essence MergerCo at a special meeting held virtually on July 8, 2026, according to remarks delivered during the meeting. J. Martin Carroll, chairperson of Esperion’s board of director
Esperion Therapeutics (ESPR) Stock Fair Value Moves Lower After Analyst Downgrades
Esperion Therapeutics is back in focus after its fair value estimate was revised from about US$6.50 to roughly US$3.19 per share, a reset of around 51% that brings price targets closer to current expectations. This shift aligns with recent Street commentary, where a wave of downgrades has analysts rethinking how execution on growth plans could affect what investors are willing to pay for the stock. In the sections that follow, you will see how these updated targets fit into the evolving...
Why Is Altimmune (ALT) Down 11.3% Since Last Earnings Report?
Altimmune (ALT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Catalyst (CPRX) Up 0.6% Since Last Earnings Report: Can It Continue?
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ESPR Stock Surges 44% in a Month: Here's What You Need to Know
Esperion shares jump nearly 44% in a month. The primary catalyst was Archimed's agreement to acquire the company in a deal valued at up to $1.1 billion, including milestone payments.